Vienna
,
Austria
15 - 19 September 2025
European Association for the Study of Diabetes 61st Annual Meeting (EASD 2025)
Presentation schedule and materials
Monday, 15 September 2025
09:00
- 17:00
CEST
Symposium
Revolutionising Cardiometabolic Health: Innovating, Transforming and Progressing Care
Alice Cheng
;
Ania Jastreboff
;
Anna Secher
;
Antje Körner
;
Arya M. Sharma
;
Athena Philis-Tsimikas
;
Carel le Roux
;
Christoph Wanner
;
Harald Sourij
;
John Buse
;
Laurent Castera
;
Linong Ji
;
Matthias Blüher
;
Melanie Davies
;
Michele Senni
;
Mikael Rydén
;
Subodh Verma
;
W. Timothy Garvey
MATERIALS AVAILABLE
Tuesday, 16 September 2025
10:15
- 10:30
CEST
ORAL PRESENTATION
Oral semaglutide and cardiovascular outcomes by baseline A1c and BMI in people with type 2 diabetes in the SOUL trial
Silvio E. Inzucchi1; Rohana Abdul Ghani2; John Deanfield3; Mads D. M. Engelmann4; G. Kees Hovingh4; Ole K. Jeppesen4; Monika Kellerer5; Kabirdev Mandavya6; Johannes F. Mann7; Nikolaus Marx8; Chantal Mathieu9; Darren K. McGuire10; Viswanathan Mohan11; Sharon L. Mulvagh12; Rodica Pop-Busui13; Neil R. Poulter14; Maria Sejersten Ripa4; Gabriela Roman15; Róbinson Sánchez García16; Michael Shechter17; John B. Buse18; on behalf of the SOUL Study Group
MATERIALS AVAILABLE
12:00
- 13:00
CEST
LBA 43
SHORT ORAL PRESENTATION
Efficacy and safety of cagrilintide 2.4 mg in adults with overweight/obesity: Data from REDEFINE 1
W. Timothy Garvey1; Lei Liu2; John Rømer2; Kirsi H. Pietiläinen3; Ketil Biering Tvermosegaard2; David C.W. Lau4
MATERIALS AVAILABLE
12:00
- 13:00
CEST
873
SHORT ORAL PRESENTATION
Improved treatment satisfaction with once-weekly IcoSema vs daily basal-bolus therapy in adults with type 2 diabetes inadequately controlled on daily basal insulin (COMBINE 3)
Paolo Fiorina1; Malik Benamar2; Sin Gon Kim3; Raluca Maltesen4; Siri Vinther2; Liming Chen5
MATERIALS AVAILABLE
12:00
- 13:00
CEST
869
SHORT ORAL PRESENTATION
Efficacy and hypoglycaemia outcomes with once-weekly IcoSema vs comparators in type 2 diabetes according to pre-trial sodium-glucose cotransporter-2 inhibitor use: a post hoc analysis of COMBINE 1–3
Linong Ji1; Jonas Dahl Andersen2; Sofie Bech Andersen3; Laura Pletsch-Borba3; Viswanathan Mohan4; Daisuke Yabe5
MATERIALS AVAILABLE
12:00
- 13:00
CEST
872
SHORT ORAL PRESENTATION
Gastrointestinal adverse events with once-weekly IcoSema: a post hoc analysis of COMBINE 1–3
André Vianna1; Jonas D Andersen2; Liming Chen3; Paolo Fiorina4; Thaís M P Rocha5; Siri Vinther5; Liana K Billings6
MATERIALS AVAILABLE
12:00
- 13:00
CEST
870
SHORT ORAL PRESENTATION
Continuous glucose monitoring-based outcomes in adults with type 2 diabetes receiving IcoSema vs comparators: post hoc analysis of COMBINE 1 and 3
Concetta Irace1; Vanja Cejvanovic2; Jonas H Larsen3; Thaís MP Rocha2; Yasuo Terauchi4; Chantal Mathieu5
MATERIALS AVAILABLE
12:00
- 13:00
CEST
871
SHORT ORAL PRESENTATION
Continuous glucose monitoring-derived model-based postprandial glucose with IcoSema vs other insulin regimens: a post hoc analysis of COMBINE 1 and 3
Christophe De Block1; Malik Benamar2; Ariel Fu2; Raluca Maltesen3; Francesco Giorgino4
MATERIALS AVAILABLE
12:00
- 13:00
CEST
LBA 45
ORAL PRESENTATION
Impact on food noise after initiating semaglutide treatment: results from a US survey (INFORM)
Timothy Arnaut1; Bríain Ó Hartaigh2; Katherine Byrne3; Shannon Duncan4; Kajsa Kvist1
MATERIALS AVAILABLE
Coming soon
12:00
- 13:00
CEST
1248
SHORT ORAL PRESENTATION
Assessing thyroid cancer risk: GLP-1 RA shows short to intermediate-term safety
Vanita Aroda1,2; Tina Vilsbøll3,4; Sune Dandanell5; Jens-Peter David5; Ceyda T P Kristiansen5; Fiona Roberts5; Michael Stellfeld5; Laszlo Hegedus6;
MATERIALS AVAILABLE
13:15
- 14:15
CEST
555
ORAL PRESENTATION
Impact of semaglutide on liver-related responses in people with metabolic dysfunction-associated steatohepatitis (MASH) with/without type 2 diabetes (T2D): Post hoc analysis of the ESSENCE trial
Elisabeth Bugianesi1; Teresa Arias-Loste2; Laurent Castera3; Nathalie Marcela Eklöf4; Won Kim5; Niels Krarup4; Bernhard Ludvik6; Philip Newsome7; Vlad Ratziu8; Mary Rinella9; Arun Sanyal10; Anca Trifan11; Thea Vestergaard4; Michael Roden12; ESSENCE study group
MATERIALS AVAILABLE
14:45
- 16:15
CEST
63
ORAL PRESENTATION
Amycretin, a novel, unimolecular glucagon-like peptide-1 and amylin receptor agonist: Results of a phase 1b/2a clinical trial
Kirsten Dahl1; Kasper Adelborg2; Sohan Dey3; Ruben Duque do Vale2; Cassandra Key4; Søren Toubro2; Ania M. Jastreboff5
MATERIALS AVAILABLE
16:15
- 16:45
CEST
Symposium
Proactive care: early detection and interdisciplinary approaches for managing chronic kidney disease and peripheral artery disease in people with T2D
Ildiko Lingvay
;
David Cherney
;
Marc P. Bonaca
MATERIALS AVAILABLE
18:00
- 19:30
CEST
Symposium
Person-centred care in obesity management: connecting with your patients
Carel le Roux
;
Paolo Sbraccia
;
Steven Kahn
;
Ildiko Lingvay
;
Domenica Rubino
MATERIALS AVAILABLE
Wednesday, 17 September 2025
09:45
- 11:15
CEST
73
ORAL PRESENTATION
REDEFINE 2: A randomised trial of combined semaglutide 2.4 mg and cagrilintide 2.4 mg for the treatment of adults with BMI ≥27 kg/m2 and type 2 diabetes
Melanie J Davies1; Harpreet S Bajaj2; Christa Broholm3; Astrid Eliasen3; W Timothy Garvey4; Carel W le Roux5; Ildiko Lingvay6; Christian Bøge Lyndgaard3; Julio Rosenstock7; Lisa von Huth Smith3; Sue D Pedersen8
MATERIALS AVAILABLE
Coming soon
09:45
- 11:15
CEST
76
ORAL PRESENTATION
Safety of semaglutide among people treated with dialysis: a pooled analysis of SUSTAIN-6, SELECT, FLOW, and SOUL
Klara R. Klein1; Anna Menacher2; Katherine R. Tuttle3; Andrea Storås2; Margit R. Andersen2; Manuel Mayrdorfer2; Ildiko Lingvay4
MATERIALS AVAILABLE
Coming soon
13:00
- 14:00
CEST
895
SHORT ORAL PRESENTATION
Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec vs once-daily basal insulin in type 2 diabetes by diabetes duration: ONWARDS 1–5
Alice YY Cheng1; Gayathri Anil2; Luis Canani3; Jonas K Lindeløv4; Siri Vinther4; Chantal Mathieu5
MATERIALS AVAILABLE
Coming soon
13:00
- 14:00
CEST
710
SHORT ORAL PRESENTATION
Effect of semaglutide on the initiation of additional glucose-lowering therapy: An analysis of the SELECT trial
Steven E Kahn1; Ole Kleist Jeppesen2; A Michael Lincoff3; Ildiko Lingvay4; Jorge Plutzky5; Anders Rasmussen Rinnov2; Donna H Ryan6; Scott S Emerson7
MATERIALS AVAILABLE
Coming soon
14:30
- 14:45
CEST
ORAL PRESENTATION
Effects of oral semaglutide on hospitalisation rates in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease: SOUL trial results
John B. Buse1; Nikolaus Marx2; Sharon L. Mulvagh3; John Deanfield4; Silvio E. Inzucchi5; Rodica Pop-Busui6; Johannes F. E. Mann7; Scott Emerson8; Neil R. Poulter9; Mads D.M. Engelmann10; G. Kees Hovingh10; Rohana Abdul Ghani11; Aslam Amod12; Stephen C. Bain13; Pardeep S. Jhund14; Aytekin Oguz15; Michael Shechter16; Alex Videmark10; Derrick Musinga17; Amin Ouahid Hessissen10; Marie Reeberg Sass10; Darren K. McGuire18; on behalf of the SOUL Study Group
MATERIALS AVAILABLE
Coming soon
14:30
- 16:00
CEST
LBA 13
ORAL PRESENTATION
CagriSema improves glycaemic outcomes across weight loss categories in adults with BMI ≥27 kg/m2 and type 2 diabetes (T2D) within the blinded continuous glucose monitoring (CGM) subgroup in REDEFINE 2
Richard Pratley1; Harpreet S. Bajaj2; Christa Broholm3; Maria M Byrne4; Mikkel Hovden Christensen3; Astrid Eliasen3; Josefine Nadia Kraft3; Ildiko Lingvay5; Sean Wharton6; Melanie J. Davies2
MATERIALS AVAILABLE
Coming soon
14:30
- 16:00
CEST
LBA 15
ORAL PRESENTATION
Pharmacokinetics, safety and tolerability of amycretin in people with renal impairment
Sine Pfeiffer Haugaard1; Tobias Karlsson1; Victoria Kegel-Hübner2; Lykke Ida Kaas Oldenburg1; Mahera Parwez3; Christoffer Wiingaard1; Anne Flint1
MATERIALS AVAILABLE
Coming soon
17:45
- 19:15
CEST
Symposium
The evolving role of GLP-1RAs for holistic cardiovascular, kidney, liver and metabolic care
Steven Kahn
;
John Wilding
;
Paola Fioretto
;
Eric Lawitz
;
Subodh Verma
MATERIALS AVAILABLE
Thursday, 18 September 2025
10:45
- 12:15
CEST
147
ORAL PRESENTATION
Effect of semaglutide on body composition and proximal muscle strength: The STEP UP trial
Jøran Hjelmesæth1; Suhas Bhat2; W Timothy Garvey3; Kristoffer Jensen Kolnes4; Ildiko Lingvay5; Niklas Kahr Rasmussen4; Julio Rosenstock6; Sean Wharton7
MATERIALS AVAILABLE
Coming soon
10:45
- 12:15
CEST
145
ORAL PRESENTATION
Effect of semaglutide 7.2 mg on anthropometric measures of obesity: The STEP UP trial
Sean Wharton1; Jøran Hjelmesæth2; Ildiko Lingvay3; Hanna Angelene K M4; Maria De Los Angeles Quiroga Pelaez5; Niklas Kahr Rasmussen5; Julio Rosenstock6; W Timothy Garvey7
MATERIALS AVAILABLE
Coming soon
10:45
- 12:15
CEST
LBA 22
ORAL PRESENTATION
Incidence of non-arteritic ischaemic optic neuropathy (NAION) across completed phase 2, 3 and 4 trials evaluating the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide
Tina Vilsbøll1,2; Dikshit A3; Lloyd Paul Aiello4; Cecilia Rönnbäck5; Michael Stellfeld5; Michael Larsen6;
MATERIALS AVAILABLE
Coming soon
10:45
- 12:15
CEST
148
ORAL PRESENTATION
Impact of once-weekly semaglutide on cardiovascular events in adults with overweight or obesity in a real-world Danish population
João Fernandes1; Timothy Arnaut1; Natalie Clausen2; Lise Meinicke Hagelund2; Mathilde Kany3; Michael Maengd4
MATERIALS AVAILABLE
Coming soon
10:45
- 12:15
CEST
146
ORAL PRESENTATION
Control of eating with semaglutide 7.2 mg in adults with obesity: The STEP UP trial
Sean Wharton1; Suhas Bhat2; Michelle Dalton3; Jøran Hjelmesæth4; Ildiko Lingvay5; Maria De Los Angeles Quiroga Pelaez6; Niklas Kahr Rasmussen6; Julio Rosenstock7; Jena S Tronieri8; W Timothy Garvey9
MATERIALS AVAILABLE
Coming soon
10:45
- 12:15
CEST
LBA OP 04
ORAL PRESENTATION
Comparative Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide on Cardiovascular Outcomes in US Medicare Beneficiaries With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
Xi Tan, PhD, PharmD1; Joanna Harton, PhD2; Yuanjie Liang, MS1; Lin Xie, MS1; Cynthia Gutierrez, MPH2; Chalak Muhammad, MD1; Caroline Swift, PhD1
MATERIALS AVAILABLE
Coming soon
10:45
- 12:15
CEST
LBA21
SHORT ORAL PRESENTATION
Semaglutide and risk reduction of major adverse limb events in diabetes: A pooled analysis of 13,975 participants from the SOUL, FLOW and STRIDE randomised trials
Subodh Verma1; Marc P. Bonaca2; Joakim Nordanstig3; John B. Buse4; Matthew A. Cavender4; Kenneth W. Mahaffey5; Richard Pratley6; Peter Rossing7; Alex Videmark8; Andrei-Mircea Catarig8; Søren Rasmussen8; Florian M. M. Baeres8; Mads D. M. Engelmann8; Darren K. McGuire9
MATERIALS AVAILABLE
Coming soon
12:15
- 12:45
CEST
Symposium
A new era of cardiometabolic care: advancing holistic treatment ambitions with amylin
Alice Cheng
;
Arya M. Sharma
MATERIALS AVAILABLE
15:30
- 17:00
CEST
190
ORAL PRESENTATION
REDEFINE 1: A randomised study of combined semaglutide 2.4 mg and cagrilintide 2.4 mg for the treatment of overweight or obesity in adults
W. Timothy Garvey1; Matthias Blüher2; Cynthia Karenina Osorto Contreras3; Melanie J. Davies4; Eva Winning Lehmann3; Kirsi H. Pietiläinen5; Domenica Rubino6; Paolo Sbraccia7; Lisa von Huth Smith3; Thomas Wadden8; Niels Zeuthen3; John Wilding9
MATERIALS AVAILABLE
Coming soon
15:30
- 17:00
CEST
181
ORAL PRESENTATION
Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec vs once-daily basal insulin in type 2 diabetes by baseline HbA1c: ONWARDS 1–5
Alice YY Cheng1; Gayathri Anil2; Luis Canani3; Jonas K Lindeløv4; Siri Vinther4; Chantal Mathieu5
MATERIALS AVAILABLE
Coming soon
17:00
- 17:30
CEST
Symposium
From at-risk to recognition: improving detection of MASH
Lise Lotte Gluud
;
Harpreet Bajaj
MATERIALS AVAILABLE
Keywords
Get notified when materials for EASD 2025 and future congresses become available:
Get notified when materials for EASD 2025 and future congresses become available:
Success
We will notify you when new materials become available for EASD 2025 and future congresses.
We will keep you updated in your inbox:
Almost Done